AI for Smarter Healthcare
DeepVessel FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
Enabling better diagnosis and treatment of patients with coronary artery disease.
Comprehensive R&D Pipeline Solution Suites
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment maintenance.
Keya Medical: world’s leading AI medical device company
Keya Medical is dedicated to the development and commercialization of deep learning-based medical devices for disease diagnosis and treatment with a goal to revolutionize the medical device industry.
Keya Medical has developed solutions for specialties including cardiology, radiology, neurology, pathology, and surgery. Since 2016, we have collaborated with 728 hospitals to improve care delivery on a global scale.
Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
The future of health data interoperability using FHIR. ONC’s Micky Tripathi provided his perspective at a recent Cambia Grove forum.
On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital.
Artificial intelligence and other advanced informatics could be applied to coronary CTA images to unlock valuable information on atherosclerotic plaque characteristics that could be used to personalize care decisions. Learn more.